Immuneering Corporation

NASDAQ (USD): Immuneering Corporation (IMRX)

Last Price

2.78

Today's Change

-0.09 (3.13%)

Day's Change

2.63 - 3.35

Trading Volume

36,115,588

Overview

Market Cap

82 Million

Shares Outstanding

29 Million

Avg Volume

5,087,743

Avg Price (50 Days)

1.23

Avg Price (200 Days)

3.38

PE Ratio

-1.03

EPS

-2.70

Earnings Announcement

07-Nov-2024

Previous Close

2.87

Open

2.74

Day's Range

2.63 - 3.35

Year Range

1.0 - 9.0

Trading Volume

36,115,588

Price Change Highlight

1 Day Change

-3.14%

5 Day Change

109.02%

1 Month Change

169.90%

3 Month Change

80.52%

6 Month Change

45.55%

Ytd Change

-62.02%

1 Year Change

-64.94%

3 Year Change

-90.24%

5 Year Change

-84.20%

10 Year Change

-84.20%

Max Change

-84.20%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment